Search

Your search keyword '"Shetty, Jeevan K."' showing total 190 results

Search Constraints

Start Over You searched for: Author "Shetty, Jeevan K." Remove constraint Author: "Shetty, Jeevan K."
190 results on '"Shetty, Jeevan K."'

Search Results

1. The burden of neurological conditions in north Africa and the Middle East, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019

2. Barriers and Enablers for Physical Activity Engagement Among Individuals From India With Type 2 Diabetes Mellitus: A Mixed-Method Study.

3. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021

4. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019

5. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021

6. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021

7. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

8. Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021

9. The burden of metabolic risk factors in North Africa and the Middle East, 1990–2019: findings from the Global Burden of Disease Study

11. Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019

12. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial

13. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

14. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019

15. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020

16. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

17. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

18. Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019

19. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

20. Total Thiols and MDA Levels in Patients with Acute Myocardial Infarction Before and After Reperfusion Therapy

22. MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

23. Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

24. POSTER: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

25. P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL

26. PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA-THALASSEMIA

27. S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL

28. S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY

30. The burden of metabolic risk factors in North Africa and the Middle East, 1990–2019: findings from the Global Burden of Disease Study

31. Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept

32. Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia

33. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019

35. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

36. Receptor for Advanced Glycation End Product, Organ Crosstalk, and Pathomechanism Targets for Comprehensive Molecular Therapeutics in Diabetic Ischemic Stroke

37. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

38. Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β-Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis

39. A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial

40. Erythroid Response in Patients with Non-Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial

41. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

42. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial

43. a systematic analysis for the Global Burden of Disease Study 2019

44. The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2019

45. Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial

46. The Effect of Traditional Home Remedies on Glycemic Control among People with Type 2 Diabetes Mellitus (T2DM)

47. sj-docx-1-tah-10.1177_20406207221134404 – Supplemental material for Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia

50. Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial

Catalog

Books, media, physical & digital resources